Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

WVE-006

Oligonucleotide · Gene silencing: alpha-1 antitrypsin (SERPINA1) · developed by Wave Life Sciences

Phase 1/2 Most advanced trial

WVE Developer

1 Registered trials

What is WVE-006?

WVE-006 is an RNA editing oligonucleotide being studied in alpha-1 antitrypsin deficiency.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Oligonucleotide
Targets: alpha-1 antitrypsin (SERPINA1)
Mechanism: Gene silencing: alpha-1 antitrypsin (SERPINA1)
Therapy area: Respiratory
Developer: Wave Life Sciences (WVE)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06405633	Phase 1/2	Alpha-1 Antitrypsin Deficiency	Active not recruiting	WVE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alpha-1 Antitrypsin Deficiency

Other drugs acting on SERPINA1

ARC-AAT Phase 2 BEAM-302 Phase 1/2 Fazirsiran Phase 2 NTLA-3001 Phase 1/2

More from Wave Life Sciences

WVE-003 Phase 1/2 WVE-004 Phase 1/2 WVE-007 Phase 1/2 WVE-120101 Phase 1/2 WVE-120102 Phase 1/2 WVE-210201 Phase 2/3 WVE-N531 Phase 1/2

Sources

ClinicalTrials.gov NCT06405633

Updated Oct 3, 2026. Something wrong or missing? Report it on the WVE page.

Follow WVE, the company behind WVE-006

See WVE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

WVE catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z